Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide [see Use in Specific Populations (8.1)]
Nevertheless, even the most effective marketed incretin, the GLP-1/GIP dual agonist tirzepatide, produces a maximum HbA1c reduction of ~2.6%, with fewer than half of participants in the SURPASS trials reaching normoglycemia (HbA1c 10%), vehicle-treated animals lost ~40% of body weight over 3 months, consistent with prior reports showing comparable reductions from ~40 g at week 10 to ~25 g by week 20 19
Treatment can also be continued until target weight is achieved
[18] [19] If you require over-the-counter remedies for more than two weeks without improvement, consult your healthcare provider
Early detection and treatment can mitigate the severity of these conditions, ensuring that patients can continue to benefit from semaglutide with minimal risk to their gallbladder health
According to peer-reviewed publications, study participants experienced weight reductions, though individual responses varied significantly
:max_bytes(150000):strip_icc()/Health-GettyImages-1393991928-6eeadfb8e68b43a6b36aba58cc85d4d9.jpg)
